Filing Analysis
💸 Securities Offering
Filed Jan 21, 2025
🟠 HIGH
Kraig Biocraft Laboratories entered into a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. to provide potential working capital through the sale of common stock.
🚩 Red Flags
- Potential for significant shareholder dilution via a standby equity program.
- The use of 'equity for cash' (SEPA) often indicates limited access to traditional debt financing.
- The commitment fee is paid in common shares, further increasing dilution.
📋 Key Facts
- Entered into SEPA with YA II PN, LTD. on January 21, 2025.
- The agreement allows for the sale of up to $10 million in common stock.
- The company will pay a $25,000 structuring fee and a commitment fee equal to 1.00% of the Commitment Amount in shares.
- Advances are limited to 100% of the average daily traded volume over the preceding five trading days.
- Investor ownership is capped at 4.99% of outstanding voting power.
🤝 Related Party Transaction
Filed Apr 01, 2024
🟡 MEDIUM
Kraig Biocraft Laboratories issued one share of Series A preferred stock to its CEO and founder, Kim Thompson, on March 26, 2024. The issuance was executed in exchange for the cancellation of $20,000 in debt owed by Mr. Thompson.
🚩 Red Flags
- Related-party transaction involving the CEO/Founder
- Debt cancellation as consideration for equity issuance to an insider
📋 Key Facts
- Date of event: March 26, 2024
- Security issued: One share of Series A preferred stock
- Recipient: Kim Thompson (CEO and founder)
- Consideration: $20,000 debt cancellation by the CEO
- Exemption used: Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.